Synergistic Effect of a Combination of Proteasome and Ribonucleotide Reductase Inhibitors in a Biochemical Model of the Yeast Saccharomyces cerevisiae and a Glioblastoma Cell Line
Authors:
- Kirill A. KulaginKKKirill A. Kulagin
- Elizaveta S. StarodubovaESElizaveta S. Starodubova
- Pamila J. OsipovaPOPamila J. Osipova
- Anastasia V. LipatovaALAnastasia V. Lipatova
- Igor A. CherdantsevICIgor A. Cherdantsev
- Svetlana V. PoddubkoSPSvetlana V. Poddubko
- Vadim L. KarpovVKVadim L. Karpov
- Dmitry S. KarpovDmitry S. Karpov
Open Access
- 3 April 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (7) , 3977
Abstract
Proteasome inhibitors are used in the therapy of several cancers, and clinical trials are underway for their use in the treatment of glioblastoma (GBM). However, GBM becomes resistant to chemotherapy relatively rapidly. Recently, the overexpression of ribonucleotide reductase (RNR) genes was found to mediate therapy resistance in GBM. The use of combinations of chemotherapeutic agents is considered a promising direction in cancer therapy. The present work aimed to evaluate the efficacy of the combination of proteasome and RNR inhibitors in yeast and GBM cell models. We have shown that impaired proteasome function results in increased levels of RNR subunits and increased enzyme activity in yeast. Co-administration of the proteasome inhibitor bortezomib and the RNR inhibitor hydroxyurea was found to significantly reduce the growth rate of S. cerevisiae yeast. Accordingly, the combination of bortezomib and another RNR inhibitor gemcitabine reduced the survival of DBTRG-05MG compared to the HEK293 cell line. Thus, yeast can be used as a simple model to evaluate the efficacy of combinations of proteasome and RNR inhibitors.Keywords
Funding Information
- Russian Science Foundation (22-24-01065)
This publication has 82 references indexed in Scilit:
- Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1Cancer Letters, 2023
- Biochemistry—Not Oncogenes—May Demystify and Defeat CancerOncology and Therapy, 2023
- Inhibiting RRM2 to enhance the anticancer activity of chemotherapyBiomedicine & Pharmacotherapy, 2021
- Survival in glioblastoma: a review on the impact of treatment modalitiesClinical and Translational Oncology, 2016
- An inexpensive replacement for dry ice in the laboratoryAnalytical Biochemistry, 2015
- Cyclin F-Mediated Degradation of Ribonucleotide Reductase M2 Controls Genome Integrity and DNA RepairCell, 2012
- An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancerEuropean Journal of Cancer, 2009
- Ribonucleotide reductase inhibitors enhance cidofovir‐induced apoptosis in EBV‐positive nasopharyngeal carcinoma xenograftsInternational Journal of Cancer, 2005
- Influence of p53 mutations on prognosis of patients with glioblastomaCancer, 2002
- Rapid and reliable protein extraction from yeastYeast, 2000